Success Stories: Chinese AI Review Lead Earns EB1A Approval for Advancing Mathematical Modeling and Drug Development

 

Client’s Testimonial:

“I am very grateful to the Chen Immigration Team for getting my case approved, especially when other companies refused to take it.”


On October 14th, 2025, we received another EB1A (Alien of Extraordinary Ability) approval for an AI Review Lead in the field of Mathematical Modeling (Approval Notice).


General Field: Mathematical Modeling

Position at the Time of Case Filing: AI Review Lead

Country of Origin: China

State of Residence at the Time of Filing: Maryland

Approval Notice Date: October 14th, 2025

Processing Time: 6 months, 27 days (Premium Processing Requested)


Case Summary:     

We are pleased to share the EB1A approval of an AI review lead from China specializing in mathematical modeling, artificial intelligence, and precision medicine. At the time of filing, he was conducting computational research in the United States to accelerate drug development and strengthen regulatory decision-making. With a proven record of publications, citations, and expert recognition, he presented a compelling case for EB1A approval.

Extraordinary Research Contributions

The client’s work integrates mathematical modeling, machine learning, and pharmacology to improve the efficiency and safety of drug development. His research produced AI algorithms that enhance personalized medicine and developed computational frameworks now referenced in the USA Government Regulatory initiatives on AI transparency and reliability. By linking theoretical models with real-world applications, his contributions advance both healthcare innovation and regulatory science in the U.S.

Academic Record and Recognition

The client holds a Ph.D. in mathematical sciences and has authored 11 peer-reviewed journal articles and 2 preprints, cited 236 times by researchers across 24 countries. Several of his papers rank among the top 10% most cited in their fields. He has completed 11 peer reviews for leading journals, served as an area chair for an international AI conference, and participated in federal grant reviews, further confirming his professional standing.

Expert Recognition

Independent experts emphasized the practical value of his research.

One recommender wrote:

“Considering the value presented by eigenvalue problem-solving methods in industries like aerospace, automotive, photonics, and medical imaging, halting [client]’s research would be damaging to critical U.S. sectors relying on advanced computational techniques for safety, precision, and innovation.”

This statement underscores the originality and real-world significance of his work.

EB1A Approval and Outlook

The I-140 EB1A petition was filed on March 17, 2025, upgraded to premium processing, and approved on October 14, 2025. With NAILG’s support, the client secured EB1A approval by demonstrating international acclaim and national importance. He continues advancing AI-driven modeling in the United States, supporting the nation’s leadership in biomedical innovation and regulatory science.